Skip to main content

Table 2 Characteristics of subgroups according to plasma glutamine concentration at admission

From: Plasma glutamine status at intensive care unit admission: an independent risk factor for mortality in critical illness

 

All

p-Gln < 400 µmol/L

p-Gln 400–930 µmol/L

p-Gln < 930 µmol/L

p-Gln ≥ 930 µmol/L

p

Number of patients

269

40

203

243

26

 

ICU mortality

7%

5%

6%

6%

19%

0.097

One-month mortality rate

10%

8%

8%

8%

23%

0.027

Six-months mortality rate

21%

20%

18%

18%

46%

0.002

SOFA

6 (3–8)

5 (3–8)

6 (3–8)

5 (3–8)

7 (5–11)

0.006

SAPS 3

55 ± 16

59 ± 14

55 ± 16

55 ± 16

57 ± 19

0.593

Age (years)

62 (50–71)

65 (52–72)

62 (51–71)

63 (51–71)

52 (37–65)

0.019

p-Gln (µmol/L)

585 (469–735)

353 (317–371)

594 (518–700)

557 (456–676)

1165 (998–1473)

< 0.001

P-TAA (mmol/L)

2.55 (2.10–3.22)

1.73 (1.51–1.95)

2.59 (2.18–3.04)

2.41 (2.06–2.95)

5.01 (4.14–6.37)

< 0.001

Liver disease [n, %]

92 (34%)

9 (23%)

61 (30%)

70 (29%)

22 (85%)

< 0.001

Kidney failure [n, %]

83 (31%)

14 (35%)

58 (29%)

72 (30%)

11 (42%)

0.187

  1. Means ± SD or median and interquartile range
  2. Significant p values are indicated in bold
  3. p-Gln, glutamine plasma concentration at admission; SOFA, Sequential Organ Failure Assessment; SAPS, Simplified Acute Physiology Score 3; P-TAA, total amino acid plasma concentration at admission; Liver disease, known liver disease, acute liver failure and/or acute liver damage; Kidney failure, kidney failure according to SAPS scoring and/or creatinine > 180 µmol/L
  4. p value indicates the difference between the two groups p-Gln < or ≥ 930 µmol/L. 
Back to article page

Critical Care

ISSN: 1364-8535